CCNB2P1: A Potential Drug Target and Biomarker for Cancer (G100132073)
CCNB2P1: A Potential Drug Target and Biomarker for Cancer
Cancer is one of the leading causes of morbidity and mortality worldwide, with over 20 million new cases and 5.5 million deaths in 2019, according to the World Health Organization (WHO). The development of new treatments and biomarkers for cancer is crucial for improving patient outcomes and increasing the overall understanding of cancer biology. One potential drug target and biomarker that has gained significant attention in recent years is CCNB2P1, a gene that has been identified as a potential drug target and biomarker for cancer.
CCNB2P1: A Potential Drug Target
The CCNB2P1 gene is located on chromosome 18 and encodes for a protein known as CCNB2P1. This protein is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers.
One of the key features of CCNB2P1 is its potential druggability. The protein is known to have multiple potential drug targets, including a hydrophobic interaction domain (HID), a transmembrane domain (TMD), and a carboxylic acid residue (CAR) that is involved in acid-base balance. These domains make CCNB2P1 an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its activity and potentially inhibit its role in cancer progression.
CCNB2P1 has also been shown to play a key role in cancer cell-to-cell interactions and has been implicated in cancer cell migration and invasion. By targeting CCNB2P1, researchers and clinicians may be able to develop new treatments for cancer that specifically target this protein and inhibit its role in cancer cell growth and progression.
CCNB2P1: A Potential Biomarker
In addition to its potential as a drug target, CCNB2P1 has also been identified as a potential biomarker for cancer. The CCNB2P1 gene has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that CCNB2P1 may be a useful biomarker for these cancers and could potentially serve as a target for new diagnostic tests or therapies.
One approach to using CCNB2P1 as a biomarker for cancer is to use its expression as a diagnostic marker to identify individuals at risk for cancer. For example, individuals with a family history of breast or ovarian cancer may undergo testing to determine if they have the CCNB2P1 gene. If they do, further testing to confirm if they have cancer associated with the gene could be done. This approach could potentially be used to identify individuals at risk for cancer and inform decisions about cancer screening and treatment.
CCNB2P1 has also been shown to be a potential biomarker for cancer in animal models. For example, studies have shown that administering small molecules or antibodies to mice with CCNB2P1 gene mutations can induce tumors that are similar to those created by human mutations. This suggests that CCNB2P1 may be a useful target for cancer therapies and could potentially be used to develop new treatments for cancer.
Conclusion
In conclusion, CCNB2P1 is a gene that has gained significant attention in recent years due to its potential as a drug target and biomarker for cancer. Its hydrophobic interaction domain, transmembrane domain, and carboxylic acid residue make it an attractive target for small molecules, antibodies, or other therapeutic agents. Additionally, its expression has been shown to play a key role in cancer cell-to-cell interactions, which may make it a useful biomarker for cancer. Further research is needed to fully understand the role of CCNB2P1 in cancer biology and to develop new treatments for this potentially devastating disease.
Protein Name: Cyclin B2 Pseudogene 1
The "CCNB2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNB2P1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27
